Post-transplant therapy in adult acute lymphoblastic leukemia patients

Post-transplant therapy with hypomethylating agent in Philadelphia chromosome negative adult acute lymphoblastic leukemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008883

Enrollment

Registered

2023-10-20

Start date

2024-01-01

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Decitabine maintenance therapy (10mg/m2 for 5 days intravenously) is administered in acute lymphoblastic leukemia patients who received allogeneic stem cell transplantation in complete remissio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who consented to the study 2) Age > 19, 1,000/uL & PLT > 50,000/uL) 6) Patients less than 100 days after allogeneic stem cell transplantation 7) Eastern Cooperative Oncology Group (ECOG) performance status 0-2 8) Patients with appropriate liver, kidney, heart function 9) A person who understands the contents of the clinical trial, is cooperative with the trial progress, and is judged to be able to participate until the end of the study

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women, or women who may become pregnant without adequate contraception 2) Previous history of hypomethylation treatment 3) Patients who have developed other malignant tumors within the past 5 years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid cancer that have been completely treated with the intention of cure 4) Other serious illnesses or medical conditions 5) Patients 100 days after allogeneic hematopoietic stem cell transplantation 6) Men who want to become pregnant or donate sperm during a clinical trial 7) Co-administration of other experimental drugs in clinical trials 8) Any other person deemed unsuitable by the researcher.

Design outcomes

Primary

Measure	Time frame
Relapse rate	—

Secondary

Measure	Time frame
Overall survival	—

Countries

Korea, Republic of

Contacts

Public ContactDong Won Baek

Kyungpook National University Hospital

vroom21@hanmail.net+82-53-200-5568

Outcome results